Floatz logo

GVAX

Myelodysplastic Syndrome

Dana-Farber Cancer InstitutevaccinePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

315 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

GVAX is also rated in:

pancreatic neoplasmDormant
B
Indicative ·
60 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →